Track topics on Twitter Track topics that are important to you
THOUSAND OAKS, Calif., Oct. 25, 2017 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced financial results for the third quarter of 2017. Key results include: Total revenues decreased 1 percent versus the third quarter of 2016 to $5.8 billion. GAAP earnings per share (EPS) increased 3 percent to $2.76. GAAP operating income decreased 3 percent to $2.4 billion and GAAP operating margin decreased 1.1 percentage points to 44.7 percent. GAAP EPS and operating income were impacted by non-cash charges associated with the Company's decision to discontinue internal development of AMG 899, an oral CETP inhibitor. Non-GAAP EPS increased 8 percent to $3.27 driven b...
Original Article: Amgen Reports Third Quarter 2017 Financial ResultsNEXT ARTICLE
The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...